

Headline: Svelte Medical Systems, Inc. Licenses Stent Design and Delivery System Technology from Cordis Corporation

New Providence, NJ, May 5, 2009—Svelte Medical Systems, Inc. is pleased to announce that it has entered into a license agreement with Cordis Corporation for certain intellectual property rights around stent design and stent delivery systems. The agreement gives Svelte Medical exclusive rights to some intellectual property related to “Stent-on-a-Wire” delivery systems as well as non-exclusive rights to several stent designs for use on the “Stent-on-a-Wire” delivery system.

“This agreement positions the company with strong intellectual property around a novel delivery system that we believe will bring benefits to clinicians and their patients around the world,” said Mark Pomeranz, President and CEO.

Svelte Medical Systems is a private company engaged in the development of highly deliverable balloon expandable stents with the focus to reduce time and cost in an angioplasty procedure. The company’s “Stent on a Wire” system is a low profile, highly flexible stent system which navigates the vasculature in a similar fashion to a traditional guidewire. This unique design may allow physicians to eliminate several steps in the current stenting procedure and reduce the need for some ancillary devices resulting in potential cost savings that could amount to as much as \$1000 per case. The company is also pursuing a drug eluting version of their “Stent-on-a-Wire” design.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

Contact: Mark Pomeranz , President/CEO, mpomeranz@sveltomedical.com 908-264-2195